ライフサイエンスコーパス: there was no significant

1 On average, there was no significant accumulation of QD outside of the bl

2 In 2006, the new ration was available to all women and there was no significant additional impact of the pregnancy-s

3 After multivariate adjustment, there was no significant association between the achieved LDL

4 onship with mortality, so that in the majority of patients, there was no significant association with survival, hazard ra

5 Between 6 and 24 months, there was no significant between-group difference in the perc

6 However, there was no significant between-group difference in the rate

7 d longer blood circulation time compared with free Dox, and there was no significant change compared with PEG-Lipo-Dox.

8 After 52 weeks of treatment with adalimumab there was no significant change from start of treatment in TB

9 ons by a median of 25 nmol/L (IQR 11-48; p=0.012); however, there was no significant change in 5-HIAA concentrations (med

10 However, there was no significant change in cACD (P = .190) and LV (P

11 hesion protein (PfTRAP) expressed in the ChAd63-MVA system, there was no significant change in immunogenicity to either v

12 declined (-3.3%/y [95% CI, -5.6% to -1.0%], P = .004), but there was no significant change in the combined outcome of de

13 Results Although there was no significant change in the utilization rate of BI

14 Energy-dispersive X-ray spectroscopy results indicate that there was no significant copper dissolution.

15 Overall, there was no significant correlation between alveolar bone vo

16 reases in the use of less invasive ventilation after birth, there was no significant decline in oxygen dependence at 36 w

17 phorus removals of 70-80% were observed in mixed batch, and there was no significant difference between aluminum and iron

18 non-inferiority threshold for the primary endpoint, because there was no significant difference between groups in mean da

19 However, there was no significant difference between mean early PPG an

20 However, there was no significant difference between the 2 interventio

21 Statistical analysis showed there was no significant difference between the ability of th

22 cy, precision and robustness, and the results revealed that there was no significant difference between the data sets obt

23 Plaque bacterial communities showed temporal stability, as there was no significant difference in beta diversity values

24 into account the index surgery and the subsequent 90 days, there was no significant difference in cost from either the p

25 In the intention-to-treat analysis, there was no significant difference in disability-free surviv

26 6%) patients in the overall cohort died within 30 days, but there was no significant difference in freedom from chronic l

27 After adjustment, there was no significant difference in in-hospital mortality

28 IL-1beta, IL-4 and IL-2 in both MCI groups (P<0.001), while there was no significant difference in inflammatory markers b

29 In terms of repeatability, there was no significant difference in measurement of any var

30 For cisplatin-etoposide vs carboplatin-paclitaxel, there was no significant difference in median progression fre

31 ased on a mean follow-up of 3.8 years (range, 0-9.4 years), there was no significant difference in overall mortality or c

32 KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival betwe

33 With a median follow-up of 31.5 months (IQR 18.9-50.8), there was no significant difference in overall survival betwe

34 At final analysis, there was no significant difference in overall survival for p

35 nd 6 months (26.8% vs. 17.1%; P = 0.007), respectively, but there was no significant difference in reduction between clas

36 In contrast, there was no significant difference in the DOX concentrations

37 roup had neutrophilic capillaritis (54% vs. 29%, P = .035), there was no significant difference in the presence of other

38 minary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-ves

39 Comparing tIOLs vs PCRIs, there was no significant difference in the UCDVA, BCDVA, and

40 ve studies which reported on posttransplant recurrence, and there was no significant difference seen in either of these e

41 Except for Black, there was no significant difference within the methods betwee

42 At 28 weeks, there was no significant effect of either benralizumab regime

43 wer fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03), whereas there was no significant effect of negative microscopic resec

44 However, there was no significant effect of treatment assignment on su

45 Similarly, there was no significant FES uptake in the 231 G521R ER xenog

46 Compared with before surgery, there was no significant increase in deliberate self-harm hos

47 reased HF rate by a factor of 2.83 (95% CI: 1.43-5.59), and there was no significant interaction with MLVD (Pinteraction

48 In subgroup analyses, there was no significant intervention effect for SBP; a signi

49 (NA) or segment 8 (NS) carried modified packaging signals, there was no significant preference for homologous packaging

50 es was significantly reduced with cannabidiol (P=0.03), but there was no significant reduction in nonconvulsive seizures.